NCT07423572

Clinical Study of Anti-CD19/BCMA Universal Chimeric Antigen Receptor T Cells (UCAR-T) in the Treatment of Refractory Idiopathic Membranous Nephropathy (IMN)

• Status: Not Yet Recruiting
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 18 (estimated)
• Sponsor: The First Affiliated Hospital of Zhejiang Chinese Medical University · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

A single arm, open-label pilot study is designed to determine the safety and effectiveness of anti-CD19/BCMA Universal Chimeric Antigen Receptor T Cells (UCAR-T) in the Treatment of Refractory Idiopathic Membranous Nephropathy (IMN)

Conditions

• Refractory Idiopathic Membranous Nephropathy

Interventions

Type	Name	Description
DRUG	CD19/BCMA-Targeted Universal Chimeric Antigen Receptor T Cells (UCAR-T) infusing	Patients will receive Fludarabine and Cyclophosphamide on day-5, -4, and -3. Single dose of CD19/BCMA-Targeted Universal Chimeric Antigen Receptor T Cells (KN3601) will infused using dose-escalation strategy.

Timeline

• Start date: 2026-02-28
• Primary completion: 2028-02-28
• Completion: 2029-09-28
• First posted: 2026-02-20
• Last updated: 2026-02-20

Locations

1 site across 1 country: China